CureVac N.V. is a biotechnology company focused on developing transformative therapeutics based on its proprietary mRNA technology platform
The company aims to create innovative treatments for various diseases, including cancers and infectious diseases, by harnessing the power of messenger RNA to instruct cells to produce proteins that can elicit a therapeutic effect. CureVac is committed to advancing its vaccine candidates and therapies through rigorous research and clinical trials, striving to deliver next-generation solutions for patients in need of advanced medical treatments.
As the bird flu virus continues to spread through the United States, the Trump administration on Tuesday ordered all communications from the Centers for Disease Control and Prevention to stop.
According to the latest data from the Centers for Disease Control, the current bird flu outbreak has caused 67 human cases of bird flu in the U.S. and one death associated with the virus.
The CDC issued a health advisory Thursday recommending that hospitalized patients who have tested positive for influenza be tested for the bird flu virus within 24 hours.
Shares of CureVac fell by 12.3% Wednesday afternoon. The pullback may stem from profit-taking after Tuesday's strong gains driven by rising concerns over U.S. respiratory illnesses.
CureVac shares have been volatile over the past week, gaining some 25%. The stock has seen increased trading volume following the U.S.'s first human death from H5N1 bird flu.
The Louisiana Department of Health on Monday reported the first human death in the U.S. related to the H5N1 bird flu virus. The CDC is also reporting high levels of acute respiratory illnesses nationwide.
Shares of CureVac are trading higher by 15% during Monday's session. The stock is gaining following a CDC report highlighting a significant increase in acute respiratory illnesses nationwide.
Small-cap growth-orientated stocks like HTCR and CVAC often outperform during bullish markets due to their sensitivity to improving economic conditions.
GSK and CureVac restructured their collaboration into a new licensing agreement, prioritizing mRNA vaccine development. GSK gains full control of vaccine candidates for influenza and COVID-19, while CureVac receives significant financial compensation and refocuses on oncology projects.
